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Congestive Heart Failure (CHF) is a progressive health problem with high mortality and morbidity
and has the potential to develop adverse drug reactions (ADRs). This study was conducted to
determine the prevalence of potential ADRs, the types of drugs that cause ADRs, the types of ADRs,
and the risk factors that affect the ADRs in CHF patients. Data were collected using medical record
of hospitalized patient at the West Nusa Tenggara (NTB) Provincial Hospital, Indonesia, in 2017
to 2019. The assessment of the causality and severity of ADRs used the Naranjo algorithm and the
Hartwig and Siegel scale. This study used 325 CHF patients’ data. Of 325 CHF patients, 223 patients
(69%) were recorded as having ADRs with 446 total cases of ADRs, consisted of 4 (0.9%) highly
probable, 187 (41.9%) probable, and 255 (57.2%) possible. The drugs that cause ADRs with a highly
probable status are bisoprolol and ramipril. The most ADRs categories were level 1 (76.0%), followed
by level 2 (17.3%), level 3 (6.5%), and level 4A (0.2%). The most affected organ systems were the
muscles, joints, and nervous system (n=136, 37.7%), followed by renal, and gastrointestinal system.
No association between ADRs with several risk factors, such as gender, age, and comorbidities. The
prevalence of ADRs in CHF patients in this study was 69%, with the highly probable category in
causing ADRs were bisoprolol and ramipril. ADRs that mostly occurred were in the mild category.
ADRs monitoring in CHF patients is especially important to achieve optimal therapeutic results.
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INTRODUCTION
Adverse drug reactions (ADRs) are adverse or undesired
responses to a drug and occur at doses typically used in
humans for prevention, diagnosis, treatment of disease,
or for modification of physiological functions (BPOM
RI, 2011; Wadhwa et al., 2018). ADRs are one of the
major problems in the health care system (Wadhwa et
al., 2018). ADRs need attention because they can lead
to decreased quality of life, increased visits to doctors,
hospital admissions, and even death (Christianie et
al., 2008). In another survey, 85% of respondents
stated that they were associated with at least one drugrelated problem, such as drug interaction, experiencing
a dangerous side effect, or receiving the wrong drug
(Alomar, 2014).
Heart failure is a progressive health problem with
high mortality and morbidity rates in both developed
and developing countries including Indonesia, even in
Indonesia the age of heart failure patients is relatively
younger than in Europe and America accompanied by a
more severe clinical appearance (PERKI, 2015). Heart
failure is a common, costly, and potentially debilitating
syndrome associated with very complex drug regimens

and many comorbidities. All of these factors can increase
the risk of exacerbation of heart failure through direct
myocardial toxicity, drug-drug interactions, or both
(Wankhede, Pardeshi, Ghorpade, & Ghongane, 2018).
Currently, interventions to prevent and treat
cardiovascular disease are available, such as
pharmacological treatments for the treatment of elevated
LDL cholesterol levels (statins), increased blood pressure
(thiazides, β-blockers, calcium channel blockers,
angiotensin converting enzyme inhibitors or angiotensin
receptor blockers) and platelet function inhibitors
(antiplatelet agents such as low-dose aspirin) (Wankhede
et al., 2018). The drugs used for the management of
cardiovascular disease are not necessarily without side
effects. They can have adverse consequences if not
properly monitored. The increasing number of drugs
in cardiac patients creates a tendency to cause drugrelated problems such as ADRs, drug-drug interactions,
etc. Cardiovascular drugs reportedly accounted for 9%
of treatment-related visits to health care providers. One
in every five heart patients is known to have ADRs and
17.9% of these are preventable, which then requires
intensive monitoring and reporting (Wadhwa et al.,
2018).

Copyright @ 2021 Authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original
author, and source are properly cited.

48

Pharm Sci Res, Vol 8 No 1, 2021

Given the consideration of cardiovascular disease as
a major problem, whereas cardiovascular drugs can
cause multiple ADRs, studies for ADRs detection and
reporting are of utmost importance. Besides, warnings
on the use of cardiovascular drugs and their limitations
in pre-marketing trials for drug evaluation still exist in
the literature in Indonesia related to pharmacovigilance.
It is necessary to evaluate post-marketing ADRs induced
by these drugs. This study aims to calculate the incidence
of ADRs as well as their severity and to see the effect of
various risk factors (sex, age, and comorbid disease) on
the incidence of ADRs in CHF patients by retrospective
data collection.
METHODS
The population in this study were CHF patients aged
more than 20 years who were hospitalized at the NTB
(Nusa Tenggara Barat/West Nusa Tenggara) Provincial
Hospital in the period 2017 to 2019, which was a total
of 1392 patients. The selection of age is because the
number of inpatient cases of CHF patients has increased
in prevalence from the age above 15 years based on data
from the Ministry of Health 2017 and over 20 years based
on data in the management information system of the
NTB Provincial Hospital. This study is a retrospective
study, so the research data were obtained from the medical
records of inpatients at the NTB Provincial Hospital.
The samples of the study were inpatients with a primary
diagnosis was CHF and consumed CHF medications for
at least a four weeks period who have received at least
one cardiovascular drug, which was 325 patients.
ADRs definition referred to in this study are according
to the Food and Drug Administration of the Republic
of Indonesia (BPOM, Badan Pengawas Obat dan
Makanan). ADRs defined as adverse or undesired
responses to a drug and occur at doses typically used in
humans for prevention, diagnosis, treatment of disease,
or for modification of physiological functions (BPOM,
2019). ADRs can be classified into six types from type A
reactions until type F reactions (WHO, MSH, & USAID,
2007). In this study, type A reactions was chosen because
it is common type of ADRs and is related to the drug
dose given and the drug’s pharmacological action, and
are associated with high morbidity and low mortality.
Side effects are an example of type A reactions. The
assessment of the incidence of side effects was obtained
from the symptoms complained by patients and from the
assessment made by medical doctor who was reported
and recorded in the medical record.
The assessment of the causality of ADRs was carried
out using the Naranjo algorithm rating scale. This
scale is a practical tool for assessing the probability
E-ISSN 2477-0612
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that a particular reaction in a patient can be attributed
to a particular drug. Meanwhile, the scale used for the
assessment of severity is the Hartwig & Siegel severity
scale. The results of the assessment using this scale are
divided into three categories, including mild, moderate,
and severe, depending on the severity of the suspected
reaction.
The instrument in this study was a patient data collection
sheet containing the patient’s identity, history of patient
drug use, patient’s subjective and objective data were
related to the incidence of ADRs as well as patient’s
symptoms and supportive laboratory data; then, ADRs
evaluation sheet with Naranjo Algorithm and ADRs
severity assessment sheet using Hartwig & Siegel scale.
Data collection was carried out by tracing the patient’s
medical records to select patients who met the inclusion
criteria (patient with CHF as main diagnosa and patients
receiving cardiovascular drugs at least four weeks) and
the data listed in the medical records became the basis
for filling out patient data tracking sheets and ADRs
evaluation sheets and ADRs severity levels. Data
collection was carried out by the researchers themselves.
Collected data were summated and were entered into
the Microsoft-excel sheet and was analyzed using
SPSS (Statistical Package for Social Science). Data
analysis was performed using univariate analysis that
categorical data were presented in the form of frequency
and percentage. While bivariate analysis is using the
Chi-square test that was performed to find out the effect
of various risk factors and incidence of ADRs. P-value
from the result of Chi-square test < 0.05 is considered
as statistically significant. The result of the study was
presented in the form of text, tables, and figures.
RESULTS AND DISCUSSION
Respondent Characteristics
Characteristics of respondents in this study were grouped
by sex, age, number of comorbid diseases, and stage
of CHF. Data on the characteristics of CHF patients as
study respondents can be seen in Table 1. In the study,
there were more male patients than female, 58% and
42% respectively. Several other studies also showed
similar results (Mehta & Cowie, 2006; Razzolini & Lin,
2015). Likewise, the data on the non-communicable
disease profile in 2016 shows that the number of cases
with a diagnosis of heart failure who are hospitalized
in hospitals in Indonesia (SIRS 2015) is more in men
than women (Kemenkes.RI, 2016). Men have a higher
incidence of heart failure, but women survive longer after
heart failure and women tend to be older with a diagnosis
of heart failure (Razzolini & Lin, 2015; Regitz-Zagrosek
et al., 2016; Strömberg & Mårtensson, 2003).
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Table 1. Number of CHF patients characteristics as
respondents
Characteristics

Total
Qty*
N = 325

Number of Patient
Sex
Men
Women
Age
20 – 60
> 60

(%)

190
135

58.5%
41.5%

181
144

55.7%
44.3%

37
127
95
55
9
1
2

11.4%
39.1%
29.2%
16.6%
2.8%
0.3%
0.6%

220
10
35
34
26

67.7%
3.1%
10.8%
10.5%
8.0%

Comorbidity
0
1
2
3
4
5
6
Stage
N/A**
1
2
3
4

* Qty: quantity
**N/A: not available (no description of stage)

The basic genetics of sex differences in the XY
chromosome configuration for males and XX for females.
Several genes on the Y chromosome are associated
with multiple cardiovascular risk factors, including
increased blood pressure, increased low-density
lipoprotein cholesterol, and a tendency to myocardial
infarction (Razzolini & Lin, 2015). Estrogens reduce
catecholamine-induced
vasoconstriction,
increase
vasodilation, and may increase β2-adrenergic receptor
response. A decrease in estrogen levels can increase
the sensitivity of the heart to catecholamine (RegitzZagrosek et al., 2016).
The data from the study showed that patients who
experienced ADRs was 56% of the patients in the adult
category (20-60 years), were more than the elderly
patients (44%). Similar things were also recorded in the
data profile on non-communicable diseases in 2016 by
the Ministry of Health, where most cases of heart failure
occurred in the 45-64 year age group (Kemenkes.RI,
2016).
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It can be seen that the comorbidity of patients with
the highest prevalence were patients who had two
comorbidities (39%) (Table 1). Various comorbidities that
occur in patients include disorders of the circulatory system
(coronary artery disease, ischemic cardiomyopathy, dilated
cardiomyopathy), the respiratory system (pneumonia,
pleural effusion), as well as endocrine and metabolic
disorders (diabetes, diabetic nephropathy). The presence
of information about comorbidities (comorbidities)
in CHF patients is important because comorbidities
can affect the treatment of CHF itself, even therapy for
comorbid diseases can worsen symptoms and conditions
of heart failure (e.g. use of non-steroids anti inflammation
drug), and drugs used for CHF and comorbidities may
interact (PERKI, 2015).
Staging in CHF patients is performed to assess the severity
of the patient’s CHF disease according to the criteria
published by the NYHA (New York Heart Association).
This is based on symptoms related to functional capacity
which include the patient’s limited physical activity,
ability to breathe normally, and/or chest pain. The results
of the CHF classification in this study (Table 1) show that
most of the patient data (68%) were not equipped with
patient staging information. Perhaps this is because not
all cardiologists who treat CHF patients are accustomed
to including patient stages on medical records. However,
this made us unable to analyze the effect of a stage in
CHF patients on the incidence of ADRs.
Drugs in the Management of CHF
The use of drugs in the treatment of CHF is mostly
polypharmacy. Furosemide is most widely prescribed
in the treatment of CHF (n=286, 23%) followed by
spironolactone (n=231, 19%) (Table 2). The combination
of the diuretic class furosemide and spironolactone can
reduce the risk of hypokalemia and hypomagnesemia,
and concomitant use with ACEI (Angiotensin Converting
Enzyme Inhibitor) may reduce comorbid in heart failure
(PERKI, 2015). The results of the same study were
reported (Rich, 2011). In a retrospective study, the results
showed that the spironolactone drug is usually combined
with the ACEI and ARB drug classes. The combination
of ACEI and ARB was frequently prescribed for patients
without established indications and was associated
with an increased risk of adverse renal outcomes.
This combination can improve ventricular function,
improve patient survival, and reduce the number of
hospitalizations (Anand & Tamura, 2012; McAlister et
al., 2011).
The next most widely used drug by CHF patients in
this study was bisoprolol (n=198 (16%). The efficacy
of using β-blocker drugs was studied in a prospective
randomized control trial with a hazard ratio of 0.86
(0.74-0.99) (Palau et al., 2020). Patients who received
E-ISSN 2477-0612
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Table 2. Frequency of the usage of CHF medications
at the NTB Provincial Hospital
Drugs

Qty*

(N=1224)**

Furosemide
Spironolactone
Bisoprolol
Lisinopril
Isosorbide Dinitrate (ISDN)
Candesartan
Ramipril
Valsartan
Amlodipin
Digoxin
Hydrochlorothiazide (HCT)
Captopril
Carvedilol
Nitroglycerin

286
231
198
42
67
77
119
26
32
117
2
5
7
15

23%
19%
16%
3%
5%
6%
10%
2%
3%
10%
0.2%
0.4%
1%
1%

* Qty: quantity
** N: amount of total drugs

digoxin and ISDN therapy were 117 (10%) and 67 (5%)
respectively. Giving a combination of digoxin and ISDN
can slow the ventricular rate, symptomatic relief, and
decrease hospital admission rates, administration of this
drug is titrated from the minimum dose then titrated
up to the target dose accompanied by drug monitoring
effect (PERKI, 2015). ISDN is commonly prescribed to
enhance activity tolerance in patients with CHF, in which
nitrate induced vasodilatation starts at a cellular level by
the activation of the enzyme. In patients with congestive
heart failure, vasodilation induces a substantial reduction
in biventricular filling pressure. Moreover, it reduces
systemic and pulmonary vascular resistance and systemic
arterial blood pressure (Redfield et al., 2015).
Nitroglycerin was administered to 15 patients (2%)
and its derivatives were used in the treatment of CHF
because of the beneficial effects of nitroglycerin, which
can reduce preload and heart muscle overload, reduce
pulmonary artery pressure, and reduce vascular and
peripheral resistance (Rich, 2011).
ADRs Incidence Rate (ADRs Causality and Severity
Assessment)
In CHF patients (n=325), the incidence of ADRs occurred
in 223 patients (69%), which was higher than patients
without ADRs (31%) (Figure 1). The higher incidence
rate in patients with ADRs compared to those without
ADRs is similar to previous study, where ADRs were
recorded in 67% patients while patients without ADRs
were 33% patients (Catananti et al., 2009).
E-ISSN 2477-0612

Figure 1. Diagram of the Incidence of ADRs in
CHF Patients at the NTB Provincial Hospital
Causality analysis is an evaluation process carried out
to determine or enforce a causal relationship between
side effects that occur or are observed and drug use
by patients (BPOM RI, 2012). Determining a clinical
event is difficult, whether the event is ADRs or due to
the patient’s primary deterioration. If it is an ADRs, then
it is necessary to know which drug caused it, as many
patients take multiple medications when they are sick,
especially if they are hospitalized.
The results of the ADRs causality assessment using the
Naranjo Algorithm scale in 446 total cases of ADRs
that occured (Table 3) showed the status of the ADRs
incidence rate were 4 (0.9%) highly probable, 187
(41.9%) probable, and 255 (57.2%) possible. The drugs
that give rise to ADRs with a highly probable status were
bisoprolol which causes bradycardia and ramipril which
causes cough.
The results of research on monitoring and reporting
adverse drug reactions due to cardiovascular drug also
showed that the most common drug class implicated in
ADRs was observed to be β-blockers especially bisoprolol
(14.68%) and the majority of patients experienced
bradycardia (10.09%) followed by hypotension (9;
8.26%) (Wadhwa et al., 2018). Meanwhile, dry and
persistent cough is a side effect of well-described
ACEI drugs and the incidence of ACEI-related cough
has been reported to be in the range of 5% to 35%.
(Dicpinigaitis, 2006). This study showed that ramiprilrelated cough occurred in 7.1% of Polish patients using
ramipril therapy (Wyskida et al., 2012). ACEI-induced
cough only occurs in susceptible individuals and is not
dose-related. Therefore, this is an idiosyncratic reaction
(Yılmaz, 2019).
The ADRs severity assessment using the Hartwig and
Siegel scale showed that the most ADRs categories
were level 1 (76.0%), followed by level 2 (17.3%),
level 3 (6.5%), and level 4A (0, 2%). Levels 1 and 2
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Table 3. Results of the naranjo algorithm causality assessment and the
severity of ADRs with Hartwig & Shiegel Scale in CHF Patients at the
NTB Provincial Hospital
Naranjo Algorithm

Incidence of ADRs

(N = 446*)

Highly Probable
Probable
Possible
Hartwig & Siegel’s Scale
Mild
Level 1
Level 2
Moderate
Level 3
Level 4A

4
187
255
Incidence of ADRs

(0.9%)
(41.9%)
(57.2%)
(N = 446*)

339
77

(76.0%)
(17.3%)

29
1

(6.5%)
(0.2%)

*N: amount of total ADRs

are included in the mild category, while levels 3 and
4A are in the moderate category. The mild severity
category of ADRs are those that do not require a change
in treatment with the suspected drug, these reactions
are relatively manageable over time without much
therapeutic intervention and do not contribute to the
length of stay (LOS) in hospital. As for the moderate
category, this reaction usually requires therapeutic
intervention but this reaction can still be resolved before
24 hours by changing drug therapy or specific treatment
so that the reaction does not occur in the future. In this
category, the ADRs reaction can cause a length of stay
of at least 1 day or the ADRs that arise can be a basis
for consideration into treatment (Surjeet & Wafai, 2012).
The target of ADRs reporting and monitoring programs
is to identify and quantify the risks associated with drug
use and thus promote rational drug use. The pharmacist’s
involvement in patient care can assist in the prevention
and early detection of ADRs (Ponnusankar, Tejaswini, &
Chaitanya, 2015).

and electrolyte disturbances (potassium, sodium). The
use of diuretic drugs can also cause hyperuricemia.
The results showed that patients with kidney disorders
had the highest increase in serum creatinine by 70
(19%) cases and the least was hyperkalemia 4 (1.1%).
ACEI class drugs such as captopril and lisinopril can
cause hyperkalemia because they work by inhibiting
the change of angiotensin I to angiotensin II, causing
a decrease in aldosterone production and will cause
an increase in potassium concentration (Prasetyo &
Chrisandyani, 2010).
It has been reported in the study at a hospital in
Iran where the percentage of ADRs was greater in
gastrointestinal after administration of CHF drugs, this is
due to drug therapy more than one that is can be a factor
in gastrointestinal disorders (Mohebbi et al., 2010). In
general, gastrointestinal disturbances are mild ADRs but
can be severe and require adjustment of therapy.

Type of ADRs in CHF Patients
Types of ADR based on suspected complaints were ADR
reactions reported by patients and reported to medical
personnel from the start of the use of CHF drugs, and
then classified according to the organ of influence. The
total number of ADR reactions that occurred was 368
cases (Table 4). The types of ADR with the most errors
were disorders of the nervous and joint systems as much
as 136 (37%), impaired kidney function by 116 (32.1%),
gastrointestinal disorders as much as 81 (22.4%) and
other complaints 40 (24%).

Another complaint that was often encountered after
administration of CHF drugs was dry cough which
occurred in 19 (5.2%) patients, the use of ACEI could
block the degradation of bradykinin and stimulate
the synthesis of substances that cause vasodilation,
including prostaglandin E2 and prostacyclin, an increase
in bradykinin increases the blood pressure-lowering
effect of ACEI but is also responsible for the side effect
of a dry cough that is frequently seen with ACEI use, the
same was reported in the study where the percentage of
ADRs incidence in the form of dry cough was the most
common side effect (Wankhede et al., 2018).

The impaired renal function that occurred in this study
was due to the use of diuretic drugs (ex: furosemide,
spironolactone) including increased serum creatinine

Heart rhythm disturbances (bradycardia) and hypotension
occurred in 11 (3%) patients, ARB class drugs can cause
a risk of renal impairment, bradycardia, hyperkalemia,
E-ISSN 2477-0612
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Table 4. Frequency of Type ADRs in CHF Patients at the NTB Provincial Hospital
Kind of ADRs

Qty
(N= 368)

(%)

Gastrointestinal system disorder

81

(22.4%)

Muscles, joints, nervous system disorder

136

(37.7%)

Skin reaction

5

(1.4%)

Heart rhythm disturbances and hypotension

11

(3.1%)

Impaired kidney function

116

(32.1%)

Others

19

(5.2%)

Total

362

(100%)

and hypotension, the same study results have been
previously reported in a Systematic Review Literature,
3,834 patients in hospital care who experienced
cardiovascular events after ARB administration but in
the mild category (Bots et al., 2019).
Skin reactions in the form of rash and itching occurred
in 5 (1.4%), reported the most common incidence of
cutaneous adverse drug reaction (CADR) is caused by
bisoprolol which is a β-Blocker group (Wankhede et al.,
2018). Management of skin reactions is generally given
antihistamine class drugs as long as the condition is still
complained of and if it is known the drug causing the
skin reaction, treatment can be continued without the
causative drug.
Relationship of risk factors and the incidence ADRs
in CHF patients
All drugs can produce ADRs, but not all patients
experience the same levels and types of ADRs. Many
factors influence the occurrence of ADRs. Some of these
factors can be changed such as smoking or alcohol intake,
others that cannot be changed such as age, presence of
other diseases, or genetic factors (Alomar, 2014). The
results of the chi-square test analysis (Table 5) showed
that the risk factors in patients had no significant effect
on the incidence of ADRs in CHF patients, such as
gender (p = 0.172), age (p = 0.846) and comorbidity
(p = 0.326). This is because in each of these data it is
seen that the highest value for the incidence of ADRs
for each risk factor is only in one type of group (Table
5). For example, for gender risk factors, the incidence
value of ADRs whether ADRs appeared or not, only
occurred in the male group, as well as the risk factors for
age and comorbidity. A systematic review examining sex
differences in ADRs to the treatment of heart failure also
showed that the study had no evidence of sex differences
in the incidence of ADRs with ARBs and β-blockers
(Bots et al., 2019).
E-ISSN 2477-0612

Table 5. Risk Factors for ADRs in CHF Patients in
NTB Provincial Hospital
Risk Factor

Incidence of ADRs

P Value

Yes

No

136
87

54
48

0.172

123
100

53
49

0.846

195
28

93
9

0.326

Sex
Men
Women
Age
20 – 60
> 60
Comorbidities
With
Without

Risk factors such as gender, age, and presence or
absence of comorbid diseases did not show a significant
association with the incidence of ADRs. Therefore, to
prove the significance of this relationship and to produce
more complex data, it is necessary to carry out further
research with a larger number of samples and different
research methods.
CONCLUSION
The prevalence of ADRs in CHF patients in this study
was 69%. However, the most prevalent severity of ADRs
in CHF patients was mild ADRs. The drugs that were
included in the highly probable category in causing
ADRs in CHF patients were bisoprolol and ramipril,
while the drugs that caused the highest level of severity
(level 4A) were bisoprolol. Therefore, ADRs monitoring
in CHF patients is especially important to achieve
optimal therapeutic results and prevent the potential for
the development of more severe ADRs.
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